crizotinib
FDA Approves Alecensa for NSCLC
The FDA approved a new indication for Genentech's Alecensa, to treat people with anaplastic lymphoma kinase ...
NOVEMBER 7, 2017
Head-to-Head Trial Finds PFS Varies Between TKIs in NSCLC
In patients with ALK-positive NSCLC, the TKI alectinib increases PFS by a year or more relative to crizotinib, ...
JUNE 1, 2017
Xalkori Approved for ROS1-Positive NSCLC
The FDA has approved crizotinib (Xalkori, Pfizer) to treat ROS1-positive metastatic NSCLC.
MARCH 11, 2016
Load more